Application of clam meat oligosaccharide in preparation of hypoglycemic drugs and preparation method of clam meat oligosaccharide

Abstract

The invention relates to application of a clam meat oligosaccharide in preparation of drugs or health foods for decreasing blood sugar and preventing and treating diabetes and a preparation method of the clam meat oligosaccharide. The optimized molecular weight range of the clam meat oligosaccharide is a 500-2000 clam meat oligosaccharide compound, and the total content is higher than 50 percent. Experimental results show that the clam meat oligosaccharide can significantly inhibit the blood sugar level and improve the glucose tolerance of model mice with alloxan-induced diabetes; the clam meat oligosaccharide has a significant effect of decreasing the blood sugar for mice with II type diabetes induced by high fat diet and STZ and the main expressions are as follows: the abnormal glucose tolerance of the mice with the II type diabetes is improved, the rise of plasma HbA1c is inhibited, the contents of hepatic glycogen and muscle glycogen are significantly increased, the utilization of hepatic glycogen is enhanced, the generation of glycogen is inhibited, the glucagon secretion is inhibited, the reserve of glycogen is enhanced, and the heteroplasia of sugar is reduced. Acute toxicity tests and researches show that the clam meat oligosaccharide has no toxic or side effects and is high in safety.

Description

technical field [0001] The invention relates to a new therapeutic application of mussel meat oligosaccharides and a preparation method thereof. Background technique [0002] With the rapid development of the economy and the acceleration of industrialization, human health is facing an increasing threat from non-communicable diseases, and the prevalence of diabetes and the number of diabetic patients have risen sharply. Diabetes and its complications have brought serious burdens to human health and social development. According to the statistics of the International Diabetes Federation (IDF), there were 151 million diabetic patients in the world in 2000, and the current diabetic patients have reached 285 million. According to the current growth rate, it is estimated that nearly 500 million people worldwide will suffer from diabetes by 2030 . It is worth noting that diabetes is not only a "disease of the rich" in developed countries, but developing countries including China h...

AI Technical Summary

Problems solved by technology

In 2008, the Diabetes Epidemiological Survey organized by the Diabetes Society (CDS) of the Chinese Medical Association showed that among people over 20 years old, the age-standardized prevalence of diabetes was 9.7%, and the proportion of prediabetes was as high as 12.8%. , which is equivalent to 1 out of 4 adults with hyperglycemia. What is more serious is that 60.7% of diabetic patients in my country have not been diagnosed and cannot be effectively treated early

At present, the molecular weight of mussel polysaccharides obtained by common extraction methods is generally relatively large, which is not easy to absorb and has weak biological activity, which limits the application of mussel polysaccharides in clinical medicine.

Images